Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer
Retrieved on:
Thursday, October 14, 2021
Large-cell lung carcinoma, Amgen, Pharma, Industry, Eli Lilly and Company, Turning Point, Entrectinib, Lists of people executed in the United States, Classification, Daiichi Sankyo, Novartis, Roche, Sanofi, Merck Group, Intelligence, ADC, Brigatinib, NSCLC, Pralsetinib, Medtech, Blueprint, Osimertinib, Chemoradiotherapy, KOL, Research, Turning Point Alcohol and Drug Centre, Alectinib, Mirati, AstraZeneca, Pharmaceutical industry, Fine chemical
A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
Key Points:
- A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
- In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
- How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
- Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?